Cambridge biotech Sarepta wins fast-track approval for the first muscular dystrophy gene therapy
The FDA limited the approval of Sarepta Therapeutics’ treatment to patients ages 4 to 5 years old who still have the ability to walk.
Stay updated with breaking news from Michael Abrams. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
The FDA limited the approval of Sarepta Therapeutics’ treatment to patients ages 4 to 5 years old who still have the ability to walk.
Animals have been catching z’s for at least half a billion years. Here’s the first evidence of an animal sleeping
An advisory panel for the US Food and Drug Administration voted unanimously Friday that the Alzheimer's drug lecanemab shows "clinical benefit" for the treatment of the disease, paving the way
(CNN) — An advisory panel for the US Food and Drug Administration voted unanimously Friday that the Alzheimer’s drug lecanemab shows “clinical benefit” for the treatment of the disease, paving
(CNN) — An advisory panel for the US Food and Drug Administration voted unanimously Friday that the Alzheimer’s drug lecanemab shows “clinical benefit” for the treatment of the disease, paving